A phase II study evaluating the efficacy of Iressa [gefitinib] plus etoposide in patients with advanced hormone refractory prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs Etoposide (Primary) ; Gefitinib (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 Jan 2018 Status changed from active, no longer recruiting to discontinued as PI left UNMC
- 12 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.